Jaguar Animal Health (NASDAQ:JAGX) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Jaguar Animal Health (NASDAQ:JAGX) from a strong sell rating to a sell rating in a research report sent to investors on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Jaguar Animal Health presently has a consensus rating of “Hold” and an average target price of $2,100.00.

Jaguar Animal Health Stock Performance

JAGX opened at $3.00 on Friday. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.50 and a quick ratio of 0.29. The business has a fifty day simple moving average of $15.24 and a 200 day simple moving average of $32.05. Jaguar Animal Health has a 1 year low of $2.53 and a 1 year high of $327.60. The company has a market capitalization of $1.11 million, a PE ratio of 0.00 and a beta of 0.01.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.